Vancomycin Enema denied as non-formulary by Humana?

Humana's specific coverage criteria for vancomycin enema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Vancomycin Enema as Non-Formulary

Vancomycin enema is a compounded pharmaceutical preparation, and compounded drugs are almost universally excluded from standard commercial formularies, which list only FDA-approved finished drug products. A non-formulary denial from Humana for vancomycin enema is therefore expected and does not reflect a judgment that the treatment is inappropriate — it reflects the structural reality of how formularies are built.

Because vancomycin enema is typically used in urgent, serious clinical situations (severe or complicated Clostridioides difficile infection with anatomical barriers to oral delivery), the appropriate pathway is a formulary exception combined with a medical-necessity appeal, not a standard formulary substitution request.

## Your Federal Appeal Rights

• Formulary exception request: File a formulary exception asking Humana to cover the compounded preparation as a medical necessity. This request must include the prescriber's documentation of why no formulary alternative can substitute for the enema route in this patient.
• Internal appeal (ACA §2719 / ERISA §503): File simultaneously with or immediately following the exception request. Preserve your formal appeal rights even while the exception is pending.
• Expedited review: Active severe C. diff infection is an urgent condition. Request expedited internal and external review when timing is clinically critical.
• External review: If the internal appeal is denied, file for IRO review within approximately four months. External reviewers are not bound by formulary structures — they assess whether coverage is required as a medical necessity.

## Documentation to Gather

1. Diagnosis and severity: Positive C. diff test results, clinical severity documentation, and hospitalization or acute-care records if applicable. 2. Formulary alternatives evaluated and excluded: For each oral or IV antibiotic on Humana's formulary for C. diff, the prescriber should document why it is not an adequate substitute for this patient — specifically addressing the anatomical or physiological reason the enema route is required. 3. Anatomical barrier documentation: Operative notes, imaging, or clinical records establishing bowel diversion, ileus, or another specific barrier to oral drug delivery reaching the affected site. 4. Compounding pharmacy documentation: If Humana requests it, provide the compounding pharmacy's documentation that the preparation meets USP standards. 5. Prescriber letter of medical necessity: A detailed letter from the treating specialist explaining why this compounded preparation is the medically necessary treatment and why formulary alternatives are inadequate, citing applicable IDSA guideline organization recommendations.

## Criteria-Mapping Strategy

Obtain Humana's formulary exception criteria and their coverage policy for compounded medications. Address each stated requirement in the appeal letter, demonstrating that the clinical circumstances meet the threshold for a medically necessary formulary exception. Emphasize that this is not a preference for a brand-name drug over a generic — it is a clinical necessity for a specific route of administration that has no formulary equivalent.